Tenet Healthcare Corporation Forecast, price target & analysts
Tenet Healthcare Corporation Target price 2025 - Analyst rating & recommendation
Tenet Healthcare Corporation Classifications & Recommendation:
Tenet Healthcare Corporation Price Target
| Target Price | $173.60 |
| Price | $130.48 |
| Potential |
33.05%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Tenet Healthcare Corporation 2026 .
The average Tenet Healthcare Corporation target price is $173.60.
This is
33.05%
register free of charge
$217.00
66.31%
register free of charge
$134.00
2.70%
register free of charge
|
|
| A rating was issued by 23 analysts: 18 Analysts recommend Tenet Healthcare Corporation to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tenet Healthcare Corporation stock has an average upside potential 2026 of
33.05%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 20.67 | 20.92 |
| 0.57% | 1.26% | |
| EBITDA Margin | 18.03% | 19.50% |
| 12.34% | 8.18% | |
| Net Margin | 15.05% | 5.44% |
| 457.55% | 63.84% |
17 Analysts have issued a sales forecast Tenet Healthcare Corporation 2025 . The average Tenet Healthcare Corporation sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Tenet Healthcare Corporation EBITDA forecast 2025. The average Tenet Healthcare Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Tenet Healthcare Corporation Analysts have issued a net profit forecast 2025. The average Tenet Healthcare Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 32.69 | 11.97 |
| 460.72% | 63.38% | |
| P/E | 10.90 | |
| EV/Sales | 1.34 |
10 Analysts have issued a Tenet Healthcare Corporation forecast for earnings per share. The average Tenet Healthcare Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Tenet Healthcare Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Tenet Healthcare Corporation...
Current Tenet Healthcare Corporation Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays | Locked ➜ Locked | Locked | Feb 13 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 13 2025 |
| Keybanc | Locked ➜ Locked | Locked | Jan 07 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Jan 06 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Dec 16 2024 |
| Wells Fargo | Locked ➜ Locked | Locked | Nov 25 2024 |
| Raymond James | Locked ➜ Locked | Locked | Nov 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays: Locked ➜ Locked
|
Feb 13 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 13 2025 |
|
Locked
Keybanc: Locked ➜ Locked
|
Jan 07 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Jan 06 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Dec 16 2024 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Nov 25 2024 |
|
Locked
Raymond James: Locked ➜ Locked
|
Nov 22 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
